Characteristics of vancomycin-resistant enterococci (VRE) isolated from medical fields in Japan by 橋本, 佑輔 et al.
1 
 
 
Characteristics of vancomycin-resistant 
enterococci (VRE)  
isolated from medical fields in Japan 
 
日本国内の医療現場より分離された 
バンコマイシン耐性腸球菌に関する解析 
 
 
 
 
 
 
 
 
 
指導教員 富 田 治 芳 
 
2 
 
 
  平成 30年 1月（作成年月） 
 
 
 
群馬大学大学院医学系研究科 
 
平成 26年入学 
 
基礎・基盤医学領域・細菌学講座・細菌学 
 
橋 本 佑 輔 
  
3 
 
CONTENTS 
Introduction…………………………………………………..…….. i 
 
 
Chapter I. ………………………………………………………..….. 1 
 
Dissemination and genetic analysis of the stealthy vanB gene 
clusters of Enterococcus faecium clinical isolates in Japan. 
I. Abstract ……………………………………………………..…....... 2 
II. Background …………………………………………………..….… 4 
III. Materials and Methods ………………………………………....….. 7 
IV. Results ……………………………………………………...…….. 14 
V. Discussion ………………………………………………………... 22 
VI. Conclusion ……………………………………………………...…28 
VII. References ………………………………………………….…….. 30 
VIII. Figures and tables……………………………………………......... 41 
 
Chapter II. ……………………..…………………………………….60 
Molecular characterization of the VanD-type vancomycin-
4 
 
resistant Enterococcus faecium clinical isolates from a fecal 
sample from a same patient after vancomycin therapy.  
I. Abstract ……………………………………….………………….. 61 
II. Background …………………………………………………….… 63 
III. Materials and Methods ………………………………………....… 64 
IV. Results and Discussion ...…………………………………….….... 66 
V. Conclusion ….……………………………………………………. .69 
VI. References ……………………………………………………....... 70 
VII. Figures and tables………………………………………….…........ 74 
i 
 
Characteristics of vancomycin-resistant enterococci (VRE) 
isolated from medical fields in Japan 
 
 
Yusuke Hashimoto 
 
 
(Supervised by Prof. Haruyoshi Tomita) 
 
 
 
Introduction 
 
Enterococci are Gram-positive bacteria and usually colonize gastrointestinal tracts 
in human. They are typical opportunistic pathogens and sometimes cause bloodstream 
infections, urinary tract infections and cholangitis in compromised hosts.  
Vancomycin (VAN) is a glycopeptide antibiotic commonly used to treat severe 
Gram-positive bacterial infections. Since vancomycin resistant enterococcus (VRE) 
was first reported in 1998, it arose as a global problem in medical fields. Due to the 
limited options for treatment, Center for Disease Control and Prevention (CDC) 
regarded VRE as a serious hazard-level threat.  
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Under the Infectious Disease Control Law in Japan (Kansenshō-Hō, Act on 
Prevention of Infectious Disease and Medical Care for Patients Suffering Infectious 
Disease of Japan), notifiable VRE is defined as enterococcal clinical isolates causing 
infectious disease and showing VAN MIC≥16mg/L. Since only approximately 100 cases 
are reported every year, the prevalence of VRE is presumed to be low in comparison 
with other countries.  
Here, we described VanB-type and VanD-type enterococci isolated in medical fields 
in Japan.  
These VanB-type Enterococcus faecium were obtained from different patients. 
These isolates showed too low-level vancomycin resistance (VAN MIC 3mg/L) and 
genetically high relatedness. In addition, these low-level VAN resistant vanB gene 
clusters had the capability to convert to a higher-level VAN resistant phenotype.  
VanD-type vancomycin resistance is a relatively rare type among nine types of 
vancomycin-resistance. Until now, only dozens of VanD-type isolates have been 
reported in the world. We described three VanD-type vancomycin resistance E. faecium 
isolates which were isolated from a same patient who had received a long-term 
vancomycin (VAN) treatment. The nucleotide sequence analysis of vanD gene clusters 
showed high identities with Ruminococcus spp. which might be a reservoir of vanD 
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gene cluster in human fecal flora, suggesting a possibility of horizontal transfer of vanD 
gene cluster.  
In this thesis, we pose potential threats of VRE in clinical settings in Japan. 
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Abstract 
Background 
VanB-type vancomycin (VAN) resistance gene clusters confer VAN resistance on 
Enterococcus spp. over a wide range of MIC levels (MIC=4–1000 mg/L). However, the 
epidemiology and the molecular characteristics of the low-level VAN resistant VanB-type 
Enterococcus still remains unclear.  
Results 
We characterized 19 isolates of VanB-type Enterococcus faecium that were not 
resistant to VAN (MIC=3 mg/L) obtained from two hospitals in Japan between 2009 and 
2010. These isolates had the same nucleotide sequences for the vanB gene cluster and 
showed identical multilocus sequence typing (MLST) (ST78) with the highly related 
profiles in pulsed-field gel electrophoresis (PFGE). The vanB gene cluster was located on 
a plasmid, and was transferable to E. faecium and E. faecalis. Notably, these low-level 
VAN resistant vanB gene clusters had the capability to convert to a higher-level VAN 
resistant phenotype (MIC≥16 mg/L) with a frequency of 10-6–10-7/parent cell in vitro. 
Most of these revertants acquired genetic mutations in the vanSB gene, while the 
remainder of the revertants probably had other mutations outside of the vanB gene cluster. 
All of the revertants we tested showed increases in the VAN-dependent expression of the 
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vanB gene cluster, suggesting that the genetic mutations affected the transcriptional 
activity and reversed the VAN resistance. Targeted mutagenesis revealed that three unique 
nucleotide substitutions in the vanB gene cluster of these strains attenuated vancomycin 
resistance. 
Conclusions 
In summary, this study indicated that stealthy VanB-type E. faecium strains that have 
the potential ability to become resistance to VAN could exist in clinical settings. 
Keywords 
VRE, antibiotic resistance, outbreak, conjugation, reversion 
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Background 
Enterococcus spp. is a typical opportunistic pathogen causing urinary tract infections, 
bloodstream infections and surgical site infections in compromised hosts. Vancomycin 
(VAN) is a glycopeptide antibiotic that inhibits peptidoglycan synthesis and is used to 
treat severe Gram-positive bacterial infections [1]. VAN resistant clusters were distributed 
among several enterococcal species [2-4]. Notably, VAN resistant enterococci (VRE) 
almost consist of Enterococcus faecalis and Enterococcus faecium. Recent reports have 
documented that VRE was first reported in England and France in 1986 [5, 6] and is now 
one of the major nosocomial pathogens in the world [2]. Due to the limited options for 
treatment, invasive infections by this pathogen are important causes of morbidity and 
mortality. For that reason, active surveillance is being carried out to prevent the spread of 
VRE [7]. The VAN resistance in VRE are classified into eight acquired gene clusters. 
These are vanA, vanB, vanD, vanE, vanG, vanL, vanM and vanN [3]. VanA- and VanB-
type VRE are the major and most important genotypes in clinical settings. VanA-type 
VRE shows high resistant levels to both VAN (MIC=64–100 mg/L) and teicoplanin 
(MIC=16–512 mg/L), whereas VanB-type VRE shows susceptibility to teicoplanin 
(MIC=0.5–1 mg/L) and various levels of resistance to VAN (MIC=4–1000 mg/L) [7]. In 
recent years, outbreak of VanB-type VRE occurred in Europe, USA and worldwide [2, 4, 
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8]. The vanB gene cluster consists of a two-component regulatory system (vanRB, vanSB) 
and five resistance genes (vanYB, vanW, vanHB, vanB, vanXB) (Fig. 1) [9]. Contrary to the 
highly conserved resistance genes, the amino acid sequences of VanSB and VanRB show 
less similarity to those of VanA-type VanS and VanR with 34% and 23% identities, 
respectively [10]. These differences are suspected as being responsible for the 
glycopeptide-resistant characteristics of VanB-type VRE [10]. The wide range in the level 
of VAN resistance of VanB (MIC=4–1000 mg/L) increases the difficulties in detecting it 
in clinical settings. A previous study reported that 55% of outbreak VanB-type isolates in 
single neonatal ICU of a hospital in Germany showed MICs of VAN that were less than 
4 mg/L [8]. Meanwhile, there is concern that such low-level VRE may cause treatment 
failure due to its conversion to a high level of resistance [11]. Indeed, in VanA-type E. 
faecium, it has been reported that low-level VAN resistant E. faecium converted to the 
VAN resistant phenotype during antibiotic therapy and this was named vancomycin-
variable E. faecium (VVE) [12-14]. In Japan, the first isolation of VRE was VanA-type 
E. faecium in 1996 [15] and the first outbreak of VRE was caused by VanB-type E. 
faecium [16]. Although the prevalence of VRE is presumed to be low in Japan in 
comparison with other countries, little is known about the prevalence of low-level VanB-
type VRE. In this study, we characterized E. faecium isolates that harbor the vanB gene 
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cluster but were not resistant to VAN, and performed genetic analysis to assess the 
responsible determinants for the too low-level VAN resistant phenotype of their vanB 
gene cluster. 
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Materials and Methods 
Bacterial strains, plasmids, growth condition, oligonucleotides, media, and 
antimicrobial reagents 
The bacterial strains and plasmids used in this study are shown in Table 1. E. faecium 
M1–10 strains and Y7–12 strains were provided by MIROKU Medical Laboratory Co. 
(Nagano, Japan) and Yamaguchi Prefectural Institute of Public Health and Environment, 
respectively. pMG2200 is the pheromone-responsive plasmid isolated from E. faecalis 
clinical isolates harboring the vanB gene cluster. pMG2200 conferred VAN resistance on 
the host strain, showing an MIC for VAN of more than 64 mg/L [16]. The oligonucleotides 
used in this study are shown in Additional file 8: Table. S3. Enterococcal strains were 
routinely grown in Todd-Hewitt broth (THB; Difco, Detroit, MI) at 37°C. Escherichia 
coli strains were grown in Luria-Bertani (LB; Difco) at 37°C. All antibiotics were 
obtained from Sigma Co. (St. Louis, MO).  
Antibiotic susceptibility test 
MICs were determined by the agar dilution method according to Clinical and 
Laboratory Standards Institutes (CLSI) guidelines (http://clsi.org/). After each strain was 
grown overnight in Mueller-Hinton broth (MHB; Nissui, Tokyo, Japan), the cultures were 
diluted 100-fold with fresh MHB. An inoculum of approximately 5x105 cells (5µl) was 
8 
 
spotted onto a series of Mueller-Hinton agar (Eiken, Tokyo, Japan) plates containing a 
range of concentrations of the test drug. After incubation at 37°C for 24 hours, the 
susceptibility was determined. The interpretation of the results was in compliance with 
standards recommended by CLSI. The breakpoints of MICs for resistance to antibiotics 
were defined as follows (mg/L); vancomycin (VAN), ≥16; teicoplanin (TEC), ≥16; 
ampicillin (AMP), ≥12.5; gentamicin (GEN), >500; kanamycin (KAN), ≥1024; 
streptomycin (STR), >1000; chloramphenicol (CHL), ≥32; tetracycline (TET), ≥16; 
erythromycin (ERY), ≥8; ciprofloxacin (CIP), ≥4 (Table 1). E. faecalis V583 and 
ATCC29212 were used as controls. 
Pulsed-field gel electrophoresis (PFGE) analysis and dendrogram 
PFGE analysis was performed as previously described [40]. Briefly, enterococci DNA 
embedded in an agarose plug was digested overnight at 37°C using SmaI (Roche, Basel, 
Switzerland), and then subjected to PFGE using a CHEF-MAPPER (Bio-Rad, CA) 
according to the manufacture’s protocol. The guidelines proposed by Tenover et al. were 
used for the interpretation of PFGE results [41]. The genetic relatedness was analyzed 
using the Dice coefficient and the dendrogram and was calculated with the clustering 
algorithm of Unweighted Pair-Group Method with an Arithmetic Mean (UPGMA)  
using FP Quest Software (Bio-Rad) [42, 43]. A lambda PFG Ladder (New England 
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BioLabs, MA) was used as the Molecular Marker (MM). 
Southern transfer and hybridization analysis 
PFGE analyses with S1 nuclease or I-CeuI were performed as described above. 
Briefly, enterococci DNA embedded in agarose plug was digested for 20 minutes at 37°C 
with S1 nuclease (Promega, WI) or overnight at 37°C using I-CeuI (New England 
BioLabs, MA), the DNAs were then subjected to PFGE using a CHEF-MAPPER (Bio-
Rad, CA) according to the manufacture’s protocol. Southern hybridization was performed 
with the digoxigenin-based non-radioisotope system of Boehringer GmbH (Mannheim, 
Germany), and Southern transfer and the hybridization procedure were carried out 
according to the manufactures`s manual and standard protocol [44]. Specific probes for 
vanB gene and the 23S rRNA gene of E. faecium were used [45].   
Multilocus sequence typing (MLST) analysis 
MLST was performed as previously described [27]. The house keeping genes atpA, 
ddl, gdh, purK, gyd, pstS and adk were sequenced and STs were determined according to 
MLST.net (http://efaecium.mlst.net/).  
Conjugation experiment 
Filter mating was performed as described previously [46]. Briefly, an overnight 
culture of the bacteria diluted 50-fold in 5 ml of fresh THB broth and pre-cultured until 
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the end of the exponential phase. 100 µl of the donor culture and 100 µl of the recipient 
culture were mixed in 5 ml of THB broth. FA2-2 or BM4105RF and wild M1 or Y7 were 
used as the recipients and donors, respectively. The donor and recipient cell mixture was 
allowed to mate at 37°C for 5 hours on 0.45 µm nitrocellulose membrane (Merck 
Millipore, Darmstadt, Germany). The mating mixture was plated on selective THB agar 
containing the appropriate antibiotics. After incubation at 37°C for 48 hours, the colonies 
that grew were isolated and purified at least twice. The frequency of conjugation was 
calculated as the number of transconjugants per donor cell. 
Isolation of the VAN-resistant revertants 
Cultures of each strain grown in THB broth at 37°C for 24 hours were plated onto a 
THB agar plate with or without VAN at concentration of 16 mg/L. Colonies grown after 
24 hour of incubation at 37°C were counted and the frequency of the rate of reversion 
was estimated from the colony-forming unit (CFU) ratio of resistant strains to total strains. 
The values were the average of three independent experiments with standard error. 
Colonies grown on THB agar plates with VAN (16 mg/L) were isolated on new THB agar 
plates containing VAN (16 mg/L). Single colony isolations were performed at least twice 
for each strain. The MICs of the resulting revertants were determined by the agar dilution 
method as described above. The nucleotide sequences of the vanB gene cluster was 
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determined as described above. 
qRT-PCR analysis 
An overnight bacterial culture was diluted 100-fold in brain heart infusion (BHI) 
medium with or without VAN (1 mg/L) and incubated at 37°C until exponential phase. 
After collection of the bacterial cells by centrifugation for 5min at 12,000 rpm, total RNA 
was prepared using a Fast RNA Pro Red Kit (Q-Biogene, Inc) and Fast Prep disintegrator 
(40 sec, speed: 6.0). The resulting RNA was further extracted with chloroform, 
precipitated with ethanol and resuspended in 0.05ml diethylpyrocarbonate (DPEC)- 
treated water. Total RNA (30 µg) was incubated with recombinant DNase1 (RNase-free) 
and RNase inhibitor (Takara Bio Inc, Shiga, Japan) at 37°C for 30 min. After extraction 
with phenol-chloroform-isoamyl alcohol (25:24:1) and chloroform-isoamyl alcohol 
(24:1), the samples were precipitated with ethanol and resuspended with 20 µl of DPEC- 
treated water. The concentration of the RNA solution was determined by a fluorescence-
based assay with Qubit 3.0 (Thermo Fisher Scientific Inc, MA). Reverse transcription 
was carried out with the PrimeScript RT Master Mix (Takara Bio Inc). Real-time PCR 
was carried out with the Thunderbird SYBR qPCR Mix (Toyobo Co., Tokyo, Japan) using 
an ABI 7500 Fast RT-PCR instrument (ABI, CA). Real-time-PCR cycled at 1min at 95°C, 
followed by 40 cycles of 15 sec at 95 °C, 15 sec at 55 °C, 1 min at 72 °C. The real-time 
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PCR primers were designed by Primer3Plus (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) (Additional file 8: Table S3). 
Kinetics of cell growth. 
Overnight bacterial cultures were diluted 100-fold in fresh THB broth with or without 
VAN at concentration of 1 mg/L. The culture was incubated at 37°C and the turbidity was 
measured at an optical density of 620 nm at each time point using a Multiskan FC 
Microplate Photometer (Thermo Fisher Scientific Inc).  
Plasmid construction and targeted mutagenesis of the vanB gene cluster  
   Targeted mutagenesis of the vanSB, vanB, vanW genes in the vanB gene cluster was 
performed as previously described [47]. Briefly, the DNA fragments to be inserted were 
constructed by PCR using the corresponding primers, as indicated in Additional file 8: 
Table S3, and inserted into the pCJK47 vector using the restriction enzyme EcoRI 
(Roche) and a DNA Ligation Kit (Takara Bio Inc.), as described previously. After 
transformation into E. coli EC1000 as previously described elsewhere, the recombinant-
expressing E. coli strains were incubated in 5ml of LB containing 300 mg/L erythromycin 
at 37°C with shaking. Recombinant plasmid DNA was extracted using the QIAprep Spin 
Miniprep Kit (QIAGEN, Hilden, Germany). The constructed plasmids were sequenced to 
confirm that the desired sequence had been inserted. Electrotransformation into 
13 
 
CK111/pCF10-101 was performed as previously described. Overnight cultures of the 
donor strain (CK111/pCF10-101, pCJK47-derivatives) and recipient strain (M1TC; E. 
faecalis FA2-2 transconjugants of M1 strain) were diluted 100-fold into fresh THB broth 
and incubated separately at 37°C for 1 hour. 100µl aliquots of the donor and recipient 
cultures were mixed with 800µl of fresh THB broth and incubated at 37°C with shaking 
at 150rpm for 12 hours, and were then spread on a BHI plate (rifampicin 25mg/L, fusidic 
acid 25mg/L, erythromycin 10mg/L and X-gal 100mg/L). After incubation at 37°C for 
32-48 hour, colonies that were blue in color were isolated and purified as these were 
expected to be integrant clones where the pCJK47-derivative plasmid had integrated into 
the chromosomal target locus of the recipient strain. These integrant clones were 
inoculated in THB and incubated at 37°C for 12 hour. After a 100-fold dilution, 100µl of 
the culture broth was plated on an MM9YEG plate supplemented with 10mM 4-Chloro-
DL-phenylalanine (SIGMA-ALDRICH Co., MO) and 40mg/L X-gal, followed by 
incubation at 37°C for 12 hours. White colonies were then isolated and purified as 
potential candidates carrying mutations within the target genes. The nucleotide sequences 
were checked to determine whether mutagenesis had occurred in the target sequences. 
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Results 
Isolation of too low-level VAN resistant E. faecium harboring the vanB gene cluster 
In 2009 and 2010, a total of nineteen VAN susceptible E. faecium strains that harbored 
the vanB gene cluster were isolated from the feces of individual in-patients during a VRE 
screening test at two hospitals located in adjacent prefectures in Japan. We designated 
these isolates M1–10 (Hospital A) and Y7–12 (Hospital B), respectively (Table 1). All 
the patients did not show any significant symptoms of bacterial infectious diseases and 
were carriers. The VanB-type VAN resistance genes were detected by PCR. All of the 19 
isolates were susceptible to VAN (MIC=3 mg/L) and teicoplanin (MIC=1 mg/L), and 
resistant to ampicillin (MIC≥128 mg/L), tetracycline (MIC=64 mg/L), erythromycin 
(MIC>256 mg/L) and ciprofloxacin (MIC=64 mg/L) (Table 1). To determine the 
correlation between their genetic backgrounds, we performed PFGE and MLST analysis 
(Fig. 1, Table 1). Based on the results from PFGE analysis, using a 85% similarity value 
as cutoff point, these 19 isolates were classified into three main clusters (I, II, and III). 
Clusters I and II were further divided into two sub-clusters (I-A/I-B and II-A/II-B), 
respectively, based on 90% of similarity value. Y7–15 strains obtained from hospital B 
were all categorized into cluster II, showing that they were highly related PFGE pattern. 
For M1–10 strains obtained from hospital A, although cluster I-A and I-B strains showed 
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more than a 85 % similarity value respectively, there was a genetic variation compared 
with the Y-series strains. MLST showed that these isolates belonged to a ST78 lineage 
(allelic profile, 15-1-1-1-1-1-1), indicating that all these too low-level VAN resistant E. 
faecium strains with the vanB gene cluster had a similar genetic background, but there is 
a slight genetic variation. 
Single nucleotide variations (SNVs) in vanB gene cluster of too low-level VAN 
resistant isolates 
To identify the determinants for too low-level VAN resistance in the M1–10 and Y7–
12 strains, we analyzed the nucleotide sequences of the vanB gene clusters in M1 and Y7, 
which were the first isolates to be detected in the respective hospitals (Fig. 2, Table 2). 
The nucleotide sequences of the vanB gene clusters of these strains were completely 
identical. Then we compared the nucleotide sequence of the vanB gene cluster of M1 and 
Y7 with that of VanB-type E. faecium BM4661, which shows a high-level VAN resistance 
(MIC=256 mg/L) [17]. Compared to the vanB gene cluster of BM4661, M1 and Y7 had 
the same single nucleotide variations leading to six amino acid substitutions in the vanB 
gene cluster (Fig. 2, Table 2). Similarly, we compared the sequences of these isolates with 
those of other VanB-type VRE in the NCBI database displaying MIC-values of VAN 
greater than 16 mg/L [16-21]. Despite various levels of resistance to VAN, those strains 
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showed high sequence identities in the vanB gene cluster (Additional file 1: Table S1). 
However, a total of three unique substitutions in VanSB (Ala124Glu), VanW (Thr92Pro) 
and VanB (Ala128Val) were detected in M1 and Y7 (Fig. 2, Table 2, Additional file 2-4: 
Fig. S1–3). 
The vanB gene cluster of M1 or Y7 is mobilized to E. faecalis and E. faecium 
The vanB gene cluster is reported to be encoded on a mobile genetic element such as 
the Tn1549, Tn1547, Tn5387 conjugative transposon [22-24]. To test the effect of the 
host genetic background on the attenuated VAN-resistance, conjugative transfer 
experiments of the vanB gene cluster were carried out. The vanB gene cluster of M1 or 
Y7 was not transferred by broth mating (data not shown), but was successfully transferred 
by filter mating to the recipient strain E. faecalis FA2-2 together with gentamicin, 
kanamycin and tetracycline resistances, and to E. faecium BM4105RF together with 
gentamicin and tetracycline resistances (Table 1). The resistance gene against kanamycin 
was thought to be co-transferred to BM4105RF. However, we could not detect this 
because this strain showed native resistance to kanamycin. The vanB gene cluster of M1 
and Y7 transferred at frequencies of around 10-6 to 10-7 per donor cell between FA2-2 or 
around 10-7 to 10-8 per donor cell between BM4105RF during filter mating. We identified 
the nucleotide sequence of the vanB gene cluster of the representative transconjugants 
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(recipient; FA2-2), designated as M1TC (donor; M1) or Y7TC (donor; Y7). It was 
confirmed that the sequence of the vanB gene clusters in M1TC or Y7TC and the 
respective donor strain coincided. The transconjugants showed low MIC values for VAN 
and teicoplanin as well as the donor strain (Table 1), indicating that neither the vanB gene 
cluster from M1 nor Y7 confers the glycopeptide resistance to the FA2-2 and the 
BM4105RF strains or to the original E. faecium host background. 
The vanB gene cluster of M1 or Y7 is located on a plasmid and transferred to a 
chromosome of the recipient 
To determine the localization of the vanB gene cluster in these strains, we performed  
Southern transfer and a hybridization analysis. Southern hybridization of the vanB gene 
probe to the ca. 330 kb and ca. 100 kb S1 nuclease-treated DNAs of M1 and Y7 indicated 
a plasmid-localization for the vanB gene cluster (Additional file 5: Fig. S4). However, co-
hybridization with the vanB gene probe and 23S rRNA gene probe to I-CeuI-digested 
DNAs were identified in M1TC and Y7TC (Additional file 6: Fig. S5). Furthermore, we 
could not identify the transfer of the original plasmid to M1TC or Y7TC (Additional file 
5: Fig. S4). These results suggested that the mobile elements including the vanB gene 
cluster were inserted on the chromosomes of the transconjugants.  
Reversion of the too low-level VAN resistance of vanB gene cluster to the higher-level 
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VAN resistance 
To test whether the vanB gene cluster in M1 and Y7 was able to revert its too low-
level VAN resistance to the higher-level VAN resistance, we performed reversion 
experiments. Each 24 hour culture of M1, Y7, M1TC and Y7TC strains without drug was 
inoculated onto a THB agar plate containing VAN at concentration of 16 mg/L, following 
incubation at 37 °C. Spontaneous VAN-resistant derivative mutants (revertants) were 
obtained with a frequency of 10-6–10-7 /cell (Table 3). The frequencies of reversion in the 
transconjugants M1TC and Y7TC were almost as same as those of M1 and Y7. To 
examine the genetic changes in the vanB gene cluster, we first checked the nucleotide 
sequence of the vanB gene cluster of the revertants derived from M1TC or Y7TC 
(identical FA2-2 genetic host background). The mutations found in the vanB gene cluster 
in these revertants, designated as M1TCR1–10 and Y7TCR1–4, were concentrated in the 
intracytoplasmic domain of VanSB (Fig. 3, Table 4). Four out of ten of the M1TCR-strains 
(40%) and three out of four Y7TCR-strains (75%) had the vanSB gene mutation. All of 
the revertants showed the higher-level VAN resistance (MIC>16 mg/L). Among them, 
M1TCR6 was the only strain showing both the VAN and teicoplanin resistant phenotype. 
This revertant had an insertion of 21bp (7 a. a.) in the intracytoplasmic domain of VanSB 
(Fig. 3, Table 4). Furthermore, two revertants with the vanB gene mutation were identified 
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in M1TCR2 and Y7TCR4. We also examined the sequence of the intracytoplasmic 
domain of the vanSB gene in the M1-derived revertants (M1R1─17) and Y7-derived 
revertants (Y7R1─7). Of these revertants, 17 revertants (71%) had mutations in the 
intracytoplasmic domain of VanSB (Fig. 3, Additional file 7: Table S2). We could not 
obtain revertants with any mutations in the vanRB, vanWB, vanHB or the vanXB genes. The 
vanSB gene encodes part of the two-component regulatory system and regulates 
transcription level of the vanB gene clusters. This result suggested that the too low-level 
VAN resistant phenotype was caused by a change in the transcription level of the vanB 
gene cluster. 
Increased expression level of the vanB gene cluster in the revertants 
The transcription of the vanB gene cluster is strictly suppressed in the absence of VAN, 
and induction by VAN via the VanSB/RB pathway is essential for mediating VAN 
resistance [9]. To test whether the reversion to increased-level VAN resistance was due to 
the change in the transcriptional level of the vanB gene cluster, we examined the 
expression level of the vanXB gene as a representative of the vanB gene cluster of these 
strains by real-time PCR analysis (Table 4). Gene expression of vanXB was not detected 
in the absence of VAN, except for M1TCR6. In the presence of VAN, there was an 
approximately 4-fold decrease of vanXB gene expression in M1TC compared to the VAN-
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resistant prototype strain FA2-2/pMG2200 (data not shown). It was previously reported 
that pMG2200 has the Tn1549-like transposon encoding vanB gene cluster and that 
pMG2200 conferred high-level VAN resistance (MIC≥64 mg/L) [16]. In contrast, there 
was ca. 6-fold increase in M1TCR3 and ca. 40-fold increase in M1TCR6 compared with  
M1TC. Additionally, the constitutive expression of vanXB gene in M1TCR6 was detected 
even in the absence of VAN (Table 4). These data suggested that the increased expression 
levels of the vanB gene cluster were associated with the higher-level VAN resistance 
phenotypes of the revertants even in M1TCR1 and M1TCR5 which had no mutations in 
vanB gene cluster. 
No burden on bacterial growth by carriage of the vanB gene cluster in the 
transconjugants and its inducible revertants 
The drug resistant determinants impose a burden on cell growth, and the biological 
cost for expressing the drug resistance is an important factor for their prevalence in host 
human tissue or any clinical setting [25, 26]. To examine the effect of the vanB gene 
clusters with various level of VAN resistances on bacterial growth, FA2-2, FA2-
2/pMG2200, M1TC, M1TCR3 or M1TCR6 was individually incubated at 37°C in THB 
and their growth curves were analyzed (Fig. 4). Individual growth curves were similar to 
each other, except for M1TCR6 in the absence of VAN. These results indicated that the 
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mobile element including the vanB gene cluster, if the genes were inducible and not 
constitutively expressed, did not reduce bacterial growth in vitro. 
Targeted mutagensis of vanB gene cluster restored the resistance to VAN 
To examine whether single nucleotide variations (Fig. 2, Table 2) in the M1/Y7-
derived vanB gene cluster are responsible for the attenuated resistance to VAN, we carried 
out targeted mutagenesis by homologous recombination with pCJK47.  
A total of three unique substitutions, in VanSB (Ala124Glu), VanW (Thr92Pro) and 
VanB (Ala128Val), were detected in M1 and Y7 (Table 2). We exchanged these three 
unique nucleotide variations to those of VanB-type VRE displaying MIC-values of VAN 
greater than 16 mg/L (Table 2, Additional file 2-4: Fig. S1-3). The mutant strain with 
VanW (274C>A; Pro92Thr) and/or VanB (383T>C; Val128Ala) did not show any 
increased-level of VAN resistance (MIC=3mg/L). However, the MIC values of VAN in 
the mutants with VanSB (371A>C; Glu124Ala) and VanW (274C>A; Pro92Thr) or VanB 
(383T>C; Val128Ala) were increased (MIC=8mg/L). Exchanges of all these three single 
nucleotide variations in M1TC restored VAN resistance (MIC=16mg/L) (Table 5). In 
particular, VanSB (371A>C; Glu124Ala) appeared to be the key substitution required for 
vancomycin resistance. 
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Discussion 
Epidemiology of M1–10 and Y7–12 E. faecium strains 
In this study, we genetically characterized the E. faecium isolates M1–10 and Y7–15 
strains, which were susceptible to VAN despite possessing the vanB gene cluster (Table 
1). These strains were derived from two unrelated hospitals, but showed similar genetic 
backgrounds belonging to ST78 (Fig. 1, Table 1). Recently, it was reported that clonal 
lineage was disseminated as a consequence of antibiotic pressure in clinical settings [27]. 
The ST78 in E. faecium is one of the important group which has spread hospitalized 
patients and belongs to Bayesian analysis of population structure (BAPS) 2-1. The BAPS 
2-1 is a hospital-adapted lineage and associated with farm animals [28]. The PFGE 
patterns of the Y7–15 strains showed highly related PFGE types, suggesting the clonal 
dissemination of these isolates in the hospital. Meanwhile, M1–10 strains showed a 
relatively small genetic variation in their PFGE pattern, and the PFGE profiles of M5 and 
M9 showed 70% similarities with those of the other M-series strains. The recombination 
occurs more frequently and has an important role in a genetic diversity in E. faecium [28, 
29]. During a nosocomial outbreak, de novo generation of vancomycin-resistant E. 
faecium by mobile element including vanB gene cluster was more frequently than cross-
transmission [30]. Taken together with the fact that M1–10 and Y7–12 strains shared an 
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completely identical vanB gene cluster and similar antimicrobial susceptibility profile, 
there seemed to be a possibility of a horizontal gene transfer and/or a long-term 
colonization sufficient for genetic rearrangement in Hospital A and a transmission 
between patients in Hospital B. 
Stealth behavior of potential VAN-resistance enterococci 
About a hundred cases of VRE infection are reported in Japan annually by National 
Institute of Infectious Disease (NIID) surveillance but there are few investigations of the 
prevalence of VRE (http://www.nih.go.jp/niid/ja/). Matsumoto et al. reported that among 
24,297 clinical samples that included feces, urine, blood, sputum, decubitus and pus, 
neither VanA- nor VanB-type VRE was detected in Kitakyusyu city in 2002 [31].  
Matsushima et al. reported the regional spread of VRE in Kyoto prefecture [32]. However, 
because of the VAN-concentrations used for the VRE screening (6 mg/L and 16 mg/L, 
respectively), there is the possibility of missing low-level VAN resistant isolates [32]. 
Under the Infectious Disease Control Law in Japan (Kansenshō-Hō, Act on Prevention 
of Infectious Disease and Medical Care for Patients Suffering Infectious Disease of 
Japan), notifiable VRE is defined as enterococcal clinical isolates causing infectious 
disease and showing VAN MIC≥16mg/L. The E. faecium isolates we reported here 
showed too low-level VAN resistance (MIC=3mg/L) that is outside the scope of this 
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definition for notifiable VRE in Japan (Table 1). Notably, we also demonstrated that 
spontaneous reversion to the higher-level VAN resistance of the too low-level resistant 
vanB-carrying E. faecium could occur with a frequency of 10-6–10-7/parent cell (Table 3). 
This frequency seems to be relatively high in comparison with the usual frequency of 
reversion to antibiotics in other bacteria [33]. These barely detectable too low-level 
resistant strains have the capacity for long-term colonization in the human gut without 
producing any symptoms, because the too low-level resistance to VAN does not affect 
bacterial fitness even in the absence of VAN (Fig. 4). Consistent with our results, Marie-
Laure Foucault et al. has reported that inactivated or inducible Tn1549 carrying the vanB 
gene cluster produces no additional fitness cost [26]. Furthermore, the transfer of this 
vanB gene cluster on the plasmid of M1 or Y7 to the chromosome of other enterococci 
indicated the risk of efficient dissemination of a resistance gene. Therefore, it should be 
considered that this “stealth behavior” of too low-level resistance vanB gene clusters is 
subjected to the active surveillance by the standard VAN screening method. 
Genetic mutations leading to the reversion phenotype 
It has been reported elsewhere that enterococcus strains harboring the VanB-type VAN 
resistance gene cluster showed various MIC level for VAN or TEC [7, 9]. However, the 
determinants involved in this variation of MIC is not understood [8]. We detected the 
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experimental reversion to the higher VAN resistance phenotype in M1 and Y7 strains, or 
in their corresponding transconjugants M1TC and Y7TC (Table 1, 3). For the genetic 
regulation of the vanB-mediated VAN resistance, the VanSB sensor protein has a pivotal 
role of both kinase and dephosphatase activity that modulates the phosphorylation level 
of VanRB. When VanSB senses VAN, the VanSB/RB system activates transcription of the 
vanB gene cluster and then mediates the VAN resistance [9]. Actually, the VAN-induced 
expression levels of vanB gene cluster were increased (by 3.6 to 39.5 fold ) in the 
revertants compared with each parent strain in our investigations (Table 4). Therefore, the 
reversion to the higher-level VAN resistance appeared to be mediated by the increased 
expression level of the vanB gene cluster. It was previously reported that various 
mutations in the vanSB gene changed the glycopeptide resistance phenotype [6, 9, 34]. 
Consistent with this, 24 strains of the 38 revertants (63%) that were tested carried the 
novel mutations in intracytoplasmic domain of vanSB gene (Fig. 3, Table 4 and Additional 
file 7: Table S2). In general, the high frequency of reverting to antibiotics resistance and 
the concentration of mutations in “one gene” indicated that the mechanism of reversion 
was loss of function of the gene rather than gain of function [33]. These mutations 
appeared to lead to the attenuated dephosphatase function of VanSB. Meanwhile, the rest 
of the revertants derived from M1TC or Y7TC did not harbor any genetic mutation in the 
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vanB gene cluster containing vanRB, vanYB, vanW, vanHB, vanB, vanXB and or the sensor 
domain of vanSB, except for M1TCR2 and Y7TCR4 carrying the mutations in the vanB 
gene (Table 4). However, these revertants with no mutation, such as M1TCR1 or 
M1TCR5 still showed increased expression of the vanB gene cluster in the presence of 
VAN (Table 4), indicating that genetic mutations outside of the vanB gene cluster must 
affect the transcriptional activity of vanB genes. Additionally, M1TCR2 had an amino 
acid substitution in the vanB gene (Table 4). According to previous reports, this amino 
acid substitution of VanB did not seem to be important for ligase function [35-37]. 
Therefore, the mechanism of reversion of M1TCR2 was presumed to be the same as that 
of M1TCR1 or M1TCR5. The possible cross talks between VanRB and cognate 
enterococcal kinase were presumed to be responsible in the previous study [38]. This 
report may provide clues about the mechanism of reversion without a mutation in the 
vanB gene cluster including the PRB/PYB promotor region. A further study is underway to 
clarify this point. Collectively, reversion from too low-level VAN resistance mediated by 
the vanB gene cluster to a higher level of resistance appears to be associated with the 
increased transcriptional expression of the vanB gene cluster, but the genetic mutation or 
the mechanism responsible for the reversion appears to be varied and not limited in the 
vanB-related genes.  
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Single nucleotide variations in the vanB gene cluster attenuated resistance to VAN 
In addition to this revertant analysis, we carried out targeted mutagenesis to examine 
whether the single nucleotide variations (Table 2) in the M1/Y7-derived vanB gene cluster 
are responsible for the attenuated resistance to VAN. There were three unique amino acid 
substitutions (Ala124Glu in VanSB, Thr92Pro in VanW and Ala128Val in VanB) in the 
M1/Y7 strain (Table 2). It was reported that the essential genes of VanB-type VAN 
resistance were vanHB, vanB and vanXB [1] and deletion of vanWB in V583 did not affect 
the VAN resistance [39]. In addition, it has been reported previously that the amino acid 
substitution in VanB (Ala128Val) did not have an impact on ligase function [35-37]. 
However, our experiment suggested that three single nucleotide variations resulting in an 
amino acid change in the vanB gene cluster appeared to have a combined impact on 
vancomycin resistance (Table 5). The MIC-values of VAN in the mutant strains without 
VanSB (371A>C; Glu124Ala) were equal to that in the parent strain (MIC=3mg/L). 
Therefore, the nucleotide sequence variation in vanSB gene is assumed to be the main 
factor, but all of the three variations lead to too low-level VAN resistance.  
 
  
28 
 
Conclusions 
It has been thought that VVE means only VanA-type VAN susceptible enterococci 
that can revert to the resistant phenotype [14]. As shown in this study, these too low-level 
VAN resistant VanB-type isolates also have the ability to revert to the higher-level VAN 
resistant phenotype. Due to the potential threat in clinical settings and the risk of treatment 
failure, these strains should be included in VVE. Further study is required to understand 
by what molecular mechanism(s) the stealthy vanB gene cluster converts to the higher-
level resistance and the responsible determinant(s) for the varied range of glycopeptide 
MIC in the VanB-type resistance enterococci. 
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Figure 1.  PFGE profiles and dendrogram of the low-level VAN resistant E. 
faecium isolates.  Bacterial DNAs were digested with SmaI and separated by pulsed-
field gel electrophoresis (PFGE). The genetic relatedness was analyzed using the Dice 
coefficient and the dendrogram was constructed with the clustering algorithm of 
Unweighted Pair-Group Method with an Arithmetic Mean (UPGMA) using FP Quest 
Software (Bio-Rad). Major clusters and subclusters of the isolates were delineated with 
85% and 90% similarity cutoff values for PFGE as indicated by the vertical solid line 
and dotted line, respectively. A lambda PFG Ladder (New England BioLabs, MA) was 
used as the Molecular Marker (MM). 
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Figure 2.  Schematic representation of the vanB gene cluster and single nucleotide 
variations in M1 and Y7 compared with the vanB gene cluster in BM4661.  
Expression of the vanB cluster genes is regulated by the two-component regulatory 
system of VanSB/VanRB. In the presence of VAN, the histidine kinase VanSB senses VAN 
and activates the transcriptional activator VanRB. Consequently, the two- component 
regulatory genes (vanRB and vanSB) and the resistance genes (vanYB, vanW, vanHB, 
vanB and vanXB) are transcribed from the VanRB-driven promoters PRB/PYB to mediate 
the VAN resistance [10]. The arrows indicate the location of nucleotide variations (and 
resulting amino acid substitutions) identified in the vanB gene cluster of M1/Y7 
compared with that of BM4661. 
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Figure 3.  Schematic representation of novel mutations in the vanSB gene of the 
revertants. VanSB contains the motifs designated as H, N, G1, F, G2 (lightly shaded 
boxes) that are the conserved motifs of histidine protein kinases [48]. The His residue 
(233) in the H box is the primary autophosphorylation site [34].The arrows and 
characters in black boxes represent mutations found in M1R, the underlined characters 
represent those in Y7R, those in boxes represent mutations in M1TCR and characters by 
themselves represent mutations in Y7TCR, respectively. 
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Figure 4.  Growth curves of the recipient, transconjugant and revertants in the 
presence or absence of VAN.  Overnight bacterial cultures were diluted 100-fold in 
fresh THB broth with (Right) or without (Left) 1 mg/L VAN. The culture was incubated 
at 37 °C and the turbidity was measured at an optical density of 620 nm (OD620) at each 
time point. The values were the mean of three independent experiments with standard 
error, each experiment was performed in triplicate. 
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Table 1.  Bacterial strains used in this study. 
VAN TEC AMP   GEN KAN STR CHL TET ERY CIP
M1 E. faecium feces 09/09 A VanB ST78 I-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
M2 E. faecium feces 10/09 A VanB ST78 I-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
M3 E. faecium feces 10/09 A VanB ST78 I-A 3 1 256 >1024 >1024 32 8 64 ＞256 32
M4 E. faecium feces 10/09 A VanB ST78 I-B 3 1 256 8 >1024 32 8 64 ＞256 64
M5 E. faecium feces 10/09 A VanB ST78 III 3 1 128 8 128 256 8 64 ＞256 64
M6 E. faecium feces 10/09 A VanB ST78 I-A 3 1 256 8 >1024 32 8 64 ＞256 64
M7 E. faecium feces 10/09 A VanB ST78 I-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
M8 E. faecium feces 10/09 A VanB ST78 I-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
M9 E. faecium feces 10/09 A VanB ST78 III 3 1 128 8 128 256 8 64 ＞256 64
M10 E. faecium feces 10/09 A VanB ST78 I-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
Y7 E. faecium feces 02/10 B VanB ST78 II-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
Y8 E. faecium feces 02/10 B VanB ST78 II-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
Y9 E. faecium feces 02/10 B VanB ST78 II-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
Y10 E. faecium feces 02/10 B VanB ST78 II-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
Y11 E. faecium feces 02/10 B VanB ST78 II-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
Y12 E. faecium feces 02/10 B VanB ST78 II-B 3 1 128 >1024 >1024 32 8 64 ＞256 64
Y13 E. faecium feces 03/10 B VanB ST78 II-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
Y14 E. faecium feces 03/10 B VanB ST78 II-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
Y15 E. faecium feces 03/10 B VanB ST78 II-A 3 1 256 >1024 >1024 32 8 64 ＞256 64
FA2-2 E. faecalis - - - - - - 1 1 2 32 128 64 8 2 0.5 1
FA2-2/pMG2200 E. faecalis - - - VanB - - 64 1 2 32 128 64 8 2 0.5 1
M1TCb E. faecalis - - - VanB - - 3 1 2 >1024 >1024 64 8 64 0.5 1
Y1TCb E. faecalis - - - VanB - - 3 1 2 >1024 >1024 64 8 64 0.5 1
BM4105RF E. faecium - - - - - - 1 1 3 8 >1024 32 2 1 0.5 2
M1TC2c E. faecium - - - VanB - - 3 1 3 >1024 >1024 32 2 128 0.5 2
Y7TC2c E. faecium - - - VanB - - 3 1 3 >1024 >1024 32 2 128 0.5 2
VRE
genotype
Multilocus
sequence
typing
PFGE
types
MIC (mg/L)a
Strain/plasmid Species Source
Date of
Isolation
(mo/yr)
Hospital
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aVAN, vancomycin; TEC, teicoplanin; AMP, ampicillin; GEN, gentamicin; KAN, kanamycin; STR, streptomycin; CHL, 
chrolamphenicol; TET, tetracycline; ERY, erythromycin; CIP, ciprofloxacin. bCorresponding transconjugants of FA2-2 
obtained by filter mating with the donor M1 or Y7 strain, respectively. cCorresponding transconjugants of BM4105RF 
obtained by filter mating with the donor M1 or Y7 strain, respectively.  
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Table 2.  Single nucleotide variations found in the vanB gene cluster of 
 
E. faecium M1 and Y7 compared to that of BM4661a. 
 
vanS B 371C>A (Ala124Glu)d
vanW 274A>C (Thr92Pro)d
vanW 392G>T (Ile131Ser)
vanB 335A>T (Glu112Val)
vanB 383C>T (Ala128Val)d
vanB 961A>G (Met321Val)
vanX B 267T>C SMc
SunstitutionsbGene
BM4661>M1/Y7
 
aThe genetic information for BM4661 (accession no.; FJ767776.1) was obtained from 
   
 the genome database in NCBI (http://www.ncbi.nlm.nih.gov/). 
 
bThe nucleotide sequences of vanB gene clusters of M1 and Y7 strains were identical. 
 
 The brackets indicate amino acid substitutions in vanB gene clusters. The numbers of  
 
 substitusions represent the location of each gene and protein. 
 
cSM, synonymous mutation. 
 
dUnique substitusions for M1 and Y7 strains (supplementary data Figure S1, S2, S3). 
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Table 3.  Frequency of reversion to VAN-resistant phenotype. 
Parent strain The frequency of reversiona
M1 (4.2±2.0) × 10-7
Y7 (1.7±1.2) × 10-6
M1TCb (2.4±0.5) × 10-7
Y7TCb (3.5±1.0) × 10-7
 
 
aFrequency was estimated from the colony-forming unit (CFU) ratio of resistant strains  
 
to total strains. 
 
bCorresponding transconjugants of M1 or Y7 strain. 
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Table 4.  Glycopeptide MICs and detected mutations in vanB gene cluster of the VAN-resistant revertants obtained from M1TC  
 
and Y7TC. 
vanS B  gene vanB  gene VAN TEC VAN (-)  VAN (+)
M1TC - - 3 1 N. D. 1
M1TCR1 N. D. N. D. 16 1 N. D. 4.4 (±1.0)
M1TCR2 N. D. 574G>A(Ala192Thr) 16 1 N. D. 3.6 (±0.5)
M1TCR3 661G>A(Glu221Lys) N. D. 16 1 N. D. 5.8 (±1.2)
M1TCR4 N. D. N. D. 16 1 - -
M1TCR5 N. D. N. D. 16 1 N. D. 4.9 (±1.4)
M1TCR7 1200-1217 del N. D. 16 1 - -
M1TCR8 N. D. N. D. 16 1 - -
M1TCR9 N. D. N. D. 16 1 - -
M1TCR10 661G>A(Glu221Lys) N. D. 32 1 - -
Y7TC - - 3 1
Y7TCR1 722C>T(Ala241Val) N. D. 16 1 - -
Y7TCR2 N. D. N. D. 16 1 - -
Y7TCR3 574G>A(Ala192Thr) N. D. 64 1 - -
Y7TCR4 1218G>C(Gly406Ala) 317C>A(Ala106Glu) 16 1 - -
39.5 (±13.9)
Strain Mutation
a MIC (mg/L)b RT-PCR (Fold change (±SE)c
M1TCR6 648₋649 ins
CTGGAGGATGAAA
N. D. 128 128 36.1 (±8.0)
 
 
aThe sequence was compared with the vanB gene cluster of the cognate parent strain, M1TC or Y7TC.  
bVAN: vancomycin, TEC: teicoplanin. 
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cReal-time PCR data represent the fold changes in vanXB transcriptional level relative to that of M1TC in the presence 
of vancomycin (1 mg/L; VAN (+)). The values were the means of three independent experiments with standard error, 
each experiment performed in duplicate. N. D.; Not detected.  
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Table 5.  Glycopeptide MICs of the MITC derivatives that had been 
introduced mutations in vanB gene cluster. 
VAN TEC
M1TC 3 1
M1TC vanS B _E124A
b 4 1
M1TC vanB V128Ab 3 1
M1TC vanW P92Tb 3 1
M1TC vanS B E124A/vanB_ V128A
b 8 1
M1TC vanS B E124A/vanW_ P92T
b 8 1
M1TC vanB V128A/vanW P92Tb 3 1
M1TC vanS B E124A/vanB_ V128A/vanW_ P92T
b 16 1
Strain MIC (mg/L)
a
 
 
aVAN, vancomycin; TEC, teicoplanin 
 
bThree unique substitusions for M1 and Y7 strains were exchanged to that of the 
reference gene of  pMG2200 by pCJK47-used homologous recombination. 
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Additional materials 
 
Figure S1.  Amino acid sequence alignment of VanSB encoded by M1/Y7 and the other VanB-type VRE 
The genetic information for VanB-type vancomycin resistant enterococci was obtained from the genome database in NCBI 
(http://www.ncbi.nlm.nih.gov/). Alignments of VanSB amino acid sequence of wild M1/Y7 with respect to typical VanB-type 
vancomycin resistant enterococci such as MLG229 (accession no.; AY655721.2), UW7606x64/3 TC1 (accession no.; CP013009.1), 
V583 (accession no.; NC_004668), Aus0085 (accession no.;NC_021994.1) and BM4661 (accession no.; FJ767776.1) were carried out 
using ClustalW. A box indicated the unique substitution to M1 /Y7 strains.  
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Figure S2. Amino acid sequence alignment of VanB encoded by M1/Y7 and the other VanB-type VRE 
The genetic information for VanB-type vancomycin resistant enterococci was obtained from the genome database in NCBI 
(http://www.ncbi.nlm.nih.gov/). Alignments of VanB amino acid sequence of wild M1/Y7 with respect to typical VanB-type vancomycin 
resistant enterococci such as MLG229 (accession no.; AY655721.2), UW7606x64/3 TC1 (accession no.; CP013009.1), V583 (accession 
no.; NC_004668), Aus0085 (accession no.;NC_021994.1) and BM4661 (accession no.; FJ767776.1) were carried out using ClustalW. A 
box indicated the unique substitution to M1 /Y7 strains.  
  
54 
 
 
Figure S3. Amino acid sequence alignment of VanW encoded by M1/Y7 and the other VanB-type VRE 
The genetic information for VanB-type vancomycin resistant enterococci was obtained from the genome database in NCBI 
(http://www.ncbi.nlm.nih.gov/). Alignments of VanW amino acid sequence of wild M1/Y7 with respect to typical VanB-type 
vancomycin resistant enterococci such as MLG229 (accession no.; AY655721.2), UW7606x64/3 TC1 (accession no.; CP013009.1), 
V583 (accession no.; NC_004668), Aus0085 (accession no.;NC_021994.1) and BM4661 (accession no.; FJ767776.1) were carried out 
using ClustalW. A box indicated the unique substitution to M1 /Y7 strains.  
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Figure S4.  PFGE of S1 nuclease-treated DNA and hybridization with vanB gene 
probes 
PFGE of S1 nuclease-treated DNAs isolated from M1, Y7, M1TC, Y7TC, FA2-2 
and V583 was performed (Left) and gel was Southern blotted and hybridized to vanB 
gene (Right). Lanes: MM, Lambda Ladder PFG Marker (New England BioLabs, MA); 
1, M1; 2, Y7; 3, M1TC; 4, Y7TC; 5, FA2-2; 6, V583.  
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Figure S5.  PFGE of I-CeuI-digested DNA and hybridization with 23S rRNA gene 
and vanB gene probes 
PFGE of I-CeuI-digested DNAs isolated from M1, Y7, M1TC, Y7TC, FA2-2 and V583 
was performed (Left) and gel was Southern blotted and hybridized to 23S rRNA gene 
(Middle) and vanB gene (Right). Lanes: MM, Lambda Ladder PFG Marker (New 
England BioLabs, MA); 1, M1; 2, Y7; 3, M1TC; 4, Y7TC; 5, FA2-2; 6, V583. 
  
57 
 
Table S1.  Oligonucleotides used in this study. 
Names Sequence (5'-3')a Description
Reference
E.faecalis_ DDL_ E1 ATCAAGTACAGTTAGTCT species specific ddl of E. faecalis (46)
E.faecalis_ DDL_ E2 ACGATTCAAAGCTAACTG species specific ddl  of E. faecalis (46)
E.faecium_ DDL_ F1 TAGAGACATTGAATATGCC species specific ddl  of E. faecium (46)
E.faecium_ DDL_ F2 TCGAATGTGCTACAATC species specific ddl  of E. faecium (46)
VanB_B1 ATGGGAAGCCGATAGTC vanB  gene of vanB  gene cluster (46)
VanB_B2 GATTTCGTTCCTCGACC vanB  gene of vanB  gene cluster (46)
VanS_E124A_EcoR I_F3 tagataGAATTCCAAGGCAGGTGTGGGATTG construction of pCJK47_vanS B_ Glu124Ala This study
VanS_E124A_EcoR I_R3 atagatGAATTCATCTCTGTGGCAGCTTCGATG construction of pCJK47_vanS B_ Glu124Ala This study
VanB_V128A_EcoR I_F3 atctatGAATTCTTGGAAAGCGGAAAGCTGG construction of pCJK47_vanB _ Val128Ala This study
VanB_V128A_EcoR I_R3 tgagatGAATTCTGTACGATGTAAAACCGGGC construction of pCJK47_vanB _ Val128Ala This study
VanW_A92T_EcoR I_F3 tcacgtGAATTCGAGACTGGCTTCCGTATTGG construction of pCJK47_vanW _ Pro92Thr This study
VanW_A92T_EcoR I_R3 tccataGAATTCTAACGCATTGATTGCCAGC construction of pCJK47_vanW _ Pro92Thr This study
VanXB_38476F_RT-PCR GAAAT GTTGCATGGC GTCCG real time PCR for vanX B This study
VanXB_38611R_RT-PCR TTTGTGCCTCGCGCAGAG real time PCR for vanX B This study
GyrB_E. faecalis _1F GGCTTTCTTCACGAGCTTTG real time PCR for gyrB This study
GyrB_E. faecalis _1R TTGTCGATAACGTCGTAGGC real time PCR for gyrB This study
 
 
aSmall letters indicate additional tag-nucleotides for plamid construction to be digested by restriction. 
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Table S2.  Mutations in intracytoplasmic domain of VanSB and glycopeptides 
MICs of the VAN-resistant revertants. 
VAN TEC
M1R1 695C>T(Ser232Phe) 32 1
M1R2 N. D. 32 1
M1R3 710C>T(Thr237Met) 32 1
M1R4 1192C>T(Glu398X) 32 1
M1R5 793G>A(Glu265Lys) 32 1
M1R6 695C>A(Ser232Tyr) 32 1
M1R7 719C>T(Ala240Val) 128 1
M1R8 751G>A(Glu251Lys) 32 1
M1R9 N. D. 128 1
M1R10 1174A>C(Thr392Pro) 32 1
M1R11 712C>A(Pro238Thr) 32 2
M1R12 N. D. 32 1
M1R13 712C＞T Pro238Ser 32 2
M1R14 N. D. 32 1
M1R15 722C＞T(Ala241Val) 32 1
M1R16 743G>A(Gly248Glu) 32 1
M1R17 719C>A(Ala240Glu) 32 1
Y7R1 N. D. 32 1
Y7R2 1199C>A(Ala400Glu) 16 1
Y7R3 1173C>A(Phe391Leu) 32 1
Y7R4 729C>A(Ser243Arg) 32 1
Y7R5 783G>T(Lys261Asn) 32 1
Y7R6 N. D. 16 1
Y7R7 N. D. 32 1
Straina
Mutations in intracytoplasmic
domain of VanSBb
MIC (mg/L)c
 
aM1R1─M1R12; revertants from M1, Y7R1─7; revertants from Y7.  
bThe sequence was compared with the vanB gene cluster of the cognate parent strain, M1 
or Y7.  
cVAN: vancomycin, TEC: teicoplanin. 
N. D.; Not detected. 
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Table S3.  Oligonucleotides used in this study. 
Names Sequence (5'-3')a Description
Reference
or source
E.faecalis_ DDL_ E1 ATCAAGTACAGTTAGTCT species specific ddl of E. faecalis (46)
E.faecalis_ DDL_ E2 ACGATTCAAAGCTAACTG species specific ddl  of E. faecalis (46)
E.faecium_ DDL_ F1 TAGAGACATTGAATATGCC species specific ddl  of E. faecium (46)
E.faecium_ DDL_ F2 TCGAATGTGCTACAATC species specific ddl  of E. faecium (46)
VanB_B1 ATGGGAAGCCGATAGTC vanB  gene of vanB  gene cluster (46)
VanB_B2 GATTTCGTTCCTCGACC vanB  gene of vanB  gene cluster (46)
VanS_E124A_EcoR I_F3 tagataGAATTCCAAGGCAGGTGTGGGATTG construction of pCJK47_vanS B_ Glu124Ala This study
VanS_E124A_EcoR I_R3 atagatGAATTCATCTCTGTGGCAGCTTCGATG construction of pCJK47_vanS B_ Glu124Ala This study
VanB_V128A_EcoR I_F3 atctatGAATTCTTGGAAAGCGGAAAGCTGG construction of pCJK47_vanB _ Val128Ala This study
VanB_V128A_EcoR I_R3 tgagatGAATTCTGTACGATGTAAAACCGGGC construction of pCJK47_vanB _ Val128Ala This study
VanW_A92T_EcoR I_F3 tcacgtGAATTCGAGACTGGCTTCCGTATTGG construction of pCJK47_vanW_ Pro92Thr This study
VanW_A92T_EcoR I_R3 tccataGAATTCTAACGCATTGATTGCCAGC construction of pCJK47_vanW_ Pro92Thr This study
VanXB_38476F_RT-PCR GAAAT GTTGCATGGC GTCCG real time PCR for vanX B This study
VanXB_38611R_RT-PCR TTTGTGCCTCGCGCAGAG real time PCR for vanX B This study
GyrB_E. faecalis _1F GGCTTTCTTCACGAGCTTTG real time PCR for gyrB This study
GyrB_E. faecalis _1R TTGTCGATAACGTCGTAGGC real time PCR for gyrB This study
 
aSmall letters indicate additional tag-nucleotides for plamid construction to be digested by restriction.
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Abstract 
   VanD type resistance was a relatively rare type among nine types of vancomycin-
resistance. Until now, several reports have described VanD-type Enterococci. In general, 
it is characterized by constitutive expression of the resistance genes due to mutations of 
vanSD or vanRD gene and host ddl mutations.  
In this report, we described three VanD-type vancomycin resistance E. faecium 
isolates that were isolated from a same patient who had received a long-term vancomycin 
(VAN) treatment. Multilocus sequence typing (MLST) revealed that these isolates 
belonged to a same lineage. Pulsed-field gel electrophoresis (PFGE) of these isolates 
showed the same profiles, suggesting that these were clonal isolates. In addition, a 
phylogenetic analysis based on the nucleotide sequences of vanD gene cluster showed 
relative relationship between these isolates and Ruminococcus spp.. 
Of three, we identified a 12-bp deletion close to a important site of ddl gene of AA620. 
In contrast, AA622 and AA624 had the intact gene. In addition, 1bp deletion resulted in 
a frameshift in VanSD sensor protein of AA620. These results indicated that the majority 
of peptidoglycan precursors in AA620 was D-Ala-D-Lac, and this led to the higher-level 
resistant phenotype than in AA622/624. According to the analysis of the molecular 
epidemiology, these findings indicated that AA620 and AA622/AA624 strains were 
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originated separately from a same parent under a pressure of VAN. Further, there might 
be a horizontal transfer of vanD gene cluster between E. faecium and anaerobic bacteria. 
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Background 
Enterococci is an opportunistic pathogen that may cause urinary tract infections and 
endocarditis in compromised host. Vancomycin resistance enterococci (VRE) is now one 
of the hospital-acquired pathogen in the world (1). Although there are nine types of 
vancomycin resistance, predominant types in clinical setting are VanA and VanB.  
VanD type E. faecium was relatively rare, and first isolated in 1991 (2). Until now, 
there are several reports with VanD-type enterococci. VanD-type resistance had been 
reported in Enterococcus faecium, E. faecalis, E. gallinarum, E. raffinosus and E. avium. 
(3-7). VanD-type resistance genes produced the precursor ending in D-Alanine-D-Lactate 
and conferred VAN resistance on Enterococcus spp (8). In general, it is characterized by 
constitutive expression of the resistance genes due to mutations of vanSD or vanRD gene 
that were composed of two component regulatory systems (5, 6), and host ddl mutations 
except some isolates (4, 9). In this report, we described three VanD-type vancomycin 
resistance E. faecium isolates which were isolated from a same patient who had received 
a long-term vancomycin (VAN) treatment, but showed different MICs of VAN and TEC. 
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Materials and methods 
Bacterial strains, growth condition, media, and antimicrobial reagents 
   The bacterial strains used in this study are shown in Table 1. Enterococcal strains were 
routinely grown in Todd-Hewitt broth (THB; Difco, Detroit, MI) at 37°C. 
Antibiotic susceptibility test 
   MICs were determined by the agar dilution method according to Clinical and 
Laboratory Standards Institutes (CLSI) guidelines (http://clsi.org/). After each strain was 
grown overnight in Mueller-Hinton broth (MHB; Nissui, Tokyo, Japan), the cultures were 
diluted 100-fold with fresh MHB. An inoculum of approximately 5x105 cells (5µl) was 
spotted onto a series of Mueller-Hinton agar (Eiken, Tokyo, Japan) plates containing a 
range of concentrations of the test drug. After incubation at 37°C for 24 hours, the 
susceptibility was determined. The interpretation of the results was in compliance with 
standards recommended by CLSI. The breakpoints of MICs for resistance to antibiotics 
were defined as follows (mg/L); vancomycin (VAN), ≥16; teicoplanin (TEC). 
Pulsed-field gel electrophoresis (PFGE) analysis and dendrogram 
PFGE analysis was performed as previously described (10). Briefly, enterococci DNA 
embedded in an agarose plug was digested overnight at 37°C using SmaI (Roche, Basel, 
Switzerland), and then subjected to PFGE using a CHEF-MAPPER (Bio-Rad, CA) 
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according to the manufacture’s protocol. The guidelines proposed by Tenover et al. were 
used for the interpretation of PFGE results (11). A lambda PFG Ladder (New England 
BioLabs, MA) was used as the Molecular Marker (MM). 
Southern transfer and hybridization analysis 
PFGE analyses with S1 nuclease or I-CeuI were performed as described above. 
Briefly, enterococci DNA embedded in agarose plug was digested for 20 minutes at 37°C 
with S1 nuclease (Promega, WI) or overnight at 37°C using I-CeuI (New England 
BioLabs, MA), the DNAs were then subjected to PFGE using a CHEF-MAPPER (Bio-
Rad, CA) according to the manufacture’s protocol. Southern hybridization was performed 
with the digoxigenin-based non-radioisotope system of Boehringer GmbH (Mannheim, 
Germany), and Southern transfer and the hybridization procedure were carried out 
according to the manufactures`s manual and standard protocol (12). Specific probes for 
vanB gene and the 23S rRNA gene of E. faecium were used (13).   
Multilocus sequence typing (MLST) analysis 
MLST was performed as previously described (14). The house keeping genes atpA, 
ddl, gdh, purK, gyd, pstS and adk were sequenced and STs were determined according to 
MLST.net (http://efaecium.mlst.net/). 
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Results and Discussion 
We obtained three VanD-type E. faecium strains from urine and stool specimens in a 
same patient. She was a 82 year-old surgical patient with abdominal aortic aneurysm. 
Perioperative antibiotic (cefmetazole, CMZ) was administered during the blood vessel 
prosthesis implantation. After the operation, she developed a sepsis and an acute 
respiratory distress syndrome (ARDS). The intravenous antibiotic treatment, 
Tazobactam/Piperacillin (TAZ/PIPC) was started to control the infection. Because of 
inefficiency of the treatment, the intravenous antibiotic therapy was changed to 
Doripenem (DRPM), followed with VAN and levofloxacin (LVFX).  
The VanD-type strain AA620 was isolated from an urine specimen 3 weeks after 
discontinuation of the administration. AA622 and AA624 were also recovered from the 
stool specimen of the same patient several weeks after the isolation of AA620. The VanD-
type resistance genes were detected by PCR in three isolates. However, these isolates 
showed different MICs of VAN and TEC. AA620 was moderate resistant to VAN 
(MIC=64 mg/L) and susceptible to teicoplanin (MIC=2 mg/L) (TEC). Compared with 
AA620, both AA622 and AA624 were relatively lower resistant to VAN (MIC=16 mg/L) 
and susceptible to TEC (MIC=1 mg/L) (Table 1).  
We performed MLST and PFGE analysis. MLST showed these isolates belonged to a 
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ST17 or a ST78 (allelic profile, 1 or 15-1-1-1-1-1-1) (Table2). Nucleotide sequence spikes 
in atpA gene of these strains overlaps, causing an allelic profile of atpA belonged to 1 or 
15. PFGE types generated using SmaI showed the same pattern (Fig. 1). According to 
these results, these isolates recovered from a same patients within 6-month period were 
interpreted as indistinguishable isolates (15). 
To detect the location of vanD gene cluster, we used the Southern blotting Co-
hybridization of both vanD gene probe and 23S rRNA gene probe to I-ceuI-digested 
DNAs was identified (Fig. 2). These results suggested that vanD gene cluster was located 
on the chromosome. In addition, we performed PFGE of S1 nuclease-treated DNAs of 
these isolates. The plasmid profile were different between AA620 and AA622/624 (Fig. 
3). However we performed the conjugative experiment, we didn’t obtain the conjugant 
strain.  
   In general, VanD-type resistance is characterized by constitutive expression of the 
resistance genes and most of isolates that harbor vanD gene cluster have genetic mutations 
for ddl gene (4). We analyzed the nucleotide sequence of the vanD gene clusters and ddl 
genes in AA620, AA622 and AA624. We constructed a phylogenetic tree and calculated 
identities for the nucleotide sequences of vanD gene clusters from some bacteria that had 
been reported harboring vanD gene cluster in NCBI database (Fig. 4, Table 3). These 
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results showed relative relationship between the nucleotide sequences of these strains and 
those of the vanD1 operon from BM4339 and CCRI-16110, compared with other strains 
(Fig. 4, Table 3). It has already reported that anaerobic bacteria were reservoirs for 
glycopeptide resistance genes such as vanD gene cluster (16). Of them, Ruminococcus 
species (strain CCRI-16110) harbored a vanD gene cluster and integrase-like protein gene 
(intD) which were similar to that of BM4339 (17). In AA620, AA622 and AA624, the 
gene order of the vanD gene cluster and intD was in accord with CCRI-16110 (Fig. 5) 
and the nucleotide sequences of vanD gene cluster were similar each other (Table 3) (17).  
We identified a 12-bp deletion in ddl gene of AA620 (Fig. 6). This deletion was 
located close to an important site for enzymatic activity (18). It suggested that this 
deletion led to reduce or impaired Ddl ligase activity. In Contrast to AA620, the 
nucleotide sequence of ddl gene in AA622 and AA624 coincided with that of E. faecium 
BM4524 that had been shown Ddl ligase activity (19). Moreover, 1bp deletion resulted 
in a frameshift in VanSD sensor protein of AA620 (Fig. 7). This frameshift led to a 
truncated protein that didin’t have four conserved domains for kinase/phosphatase 
activities. The similar mutation had been already reported (4), and this might cause 
constitutive expression of resistance genes. Contrary to AA620, 3bp insertions in vanSD 
gene had been founded in AA622/624 (Fig. 7). These findings indicated that the majority 
69 
 
of peptidoglycan precursors in AA620 was D-Ala-D-Lac, and this led to the higher-level 
resistant phenotype than in AA622/624.  
Here, we described three VanD-type vancomycin resistance E. faecium isolates that 
were isolated from a same patient who had received a long-term vancomycin (VAN) 
treatment. According to the analysis of the molecular epidemiology, these findings 
indicated that AA620 and AA622/AA624 strains were originated separately from a same 
parent under a pressure of VAN. The nucleotide sequence analysis of vanD gene cluster 
and intD in these strain showed high nucleotide sequence identities with that of CCRI-
16110. This strain was Ruminococcus spp. and might be a reservoir of vanD gene cluster 
(17). We couldn’t obtain the other bacteria like Ruminococcus spp. that harbored vanD 
gene cluster from this patient, but this doesn’t rule out the possibility of the transfer of 
vanD gene cluster in this patient. Further  
 
Conclusion 
Because of the high prevalence of vanD gene cluster in human fecal flora (16), we 
think a surveillance for enterococci harboring vanD gene cluster is required in a medical 
field. 
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Figure 1.  PFGE of smaI-digested DNA. 
PFGE of smaI-digested DNAs isolated from AA620, AA622 and AA624 was 
performed. MM, Lambda Ladder PFG Marker (New England BioLabs, MA); 1, AA620; 
2, AA622; 3, AA624. 
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Figure 2.  PFGE of I-CeuI-digested DNA and hybridization with 23S rRNA gene 
and vanD gene probes. 
PFGE of I-CeuI-digested DNAs isolated from AA620, AA622, AA624 and  
FA2-2 was performed (Left) and gel was Southern blotted and hybridized to  
23S rRNA gene (Middle) and vanD gene (Right). Lanes: MM, Lambda Ladder  
PFG Marker (New England BioLabs, MA); 1, AA620; 2, AA622; 3, AA624; 4,  
FA2-2. 
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Figure 3.  PFGE of S1 nuclease-treated DNA 
PFGE of S1 nuclease-treated DNAs isolated from AA620, AA622, AA624 and FA2-
2 was performed. Lanes: MM, Lambda Ladder PFG Marker (New England BioLabs, 
MA); 1, FA2-2; 2, AA620; 3, AA622; 4, AA624. 
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Figure 4.  Phylogenetic tree based on the sequences of vanD gene clusters. 
The genetic information for VanD-type vancomycin resistant enterococci was obtained 
from the genome database in NCBI (http://www.ncbi.nlm.nih.gov/). Phylogenetic tree 
based on vanD gene cluster sequences of AA620 with respect to typical strains 
harboring vanD gene cluster such as BM4339 (accession no.;AF130997.1), CCRI-
16110 (accession no.;EF508033.1), N97-330 (accession no.;AF175293.1), A902 
(accession no.;EU999036.1), N03-0072 (accession no.;AY489045.1), GV5 (accession 
no.;AB242319.1), N15-508 (accession no.; KT825491.1), N04-0414 (accession no.; 
DQ172830.1) and 10/96A (accession no.; AY082011.1) were carried out using 
Neighbor-joining method. 
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Figure 5.  Schematic representation of the vanD gene cluster of AA620, AA622 
and AA624. 
The vanD cluster harbored the two-component regulatory system genes (vanRD and 
vanSD) and the resistance genes (vanYD, vanHD, vanD and vanXD). In the downstream 
region of vanXD gene, a putative integrase-like protein gene (intD) was located. 
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Figure 6.  Nucleotide sequence alignment of ddl gene encoded by AA620, AA622 
and AA624 compared with BM4524 
The genetic information for enterococci was obtained from the genome database in 
NCBI (http://www.ncbi.nlm.nih.gov/). Alignments of ddl gene sequence of AA620, 
AA622 and AA624 with respect to typical E. faecium strain BM4524 (accession no.; 
AF550665.1) were carried out using ClustalW. 
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Figure 7. Amino acid sequence alignment of VanSD encoded by AA620, AA622, 
AA624 and the other VanD-type VRE. 
The genetic information for VanD-type vancomycin resistant enterococci was obtained 
from the genome database in NCBI (http://www.ncbi.nlm.nih.gov/). Alignments of 
VanSD amino acid sequence of AA620/622/624 with respect to typical VanD-type 
vancomycin resistant enterococci such as BM4339 (AF130997.1), N97-330 (accession 
no.; AF175293.1), 10/96A (accession no.; AY082011.1), A902 (accession 
no.;EU999036.1), GV5 (accession no.;AB242319.1) and MRY12-252 (unpublished) 
were carried out using ClustalW. Solid lines indicated the deletion of AA620 or the 
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insertion of AA622/624, respectively. Dot lines indicated the functional domain of 
VanSD protein. 
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Table 1.  Bacterial strains used in this study. 
VRE
genotype VAN TEC
AA620 E. faecium vanD 64 2
AA622 E. faecium vanD 16 1
AA624 E. faecium vanD 16 1
Strain/plasmid Species
MIC (mg/L)a
 
aVAN, vancomycin; TEC, teicoplanin 
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Table 2.  MLST analysis of the strains used in this study. 
atpA ddl gdh purK gyd pstS adk ST
AA620 1 or 15   (1a ) 1 1 1 1 1 17 or 78
AA622 1 or 15 1 1 1 1 1 1 17 or 78
AA624 1 or 15 1 1 1 1 1 1 17 or 78  
a12bp deletions were identified in the sequence of ddl gene of AA620. 
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Table 3.  Nucleotides and amino acid identities of vanD gene cluster. 
Straina AA620 BM4339 CCRI-16110 N97-330 A902 N03-0072 GV5 N15-508 N04-0414 10/96A
AA620 - 98.74 98.01 96.52 91.66 85.31 80.46 72.73 72.69 56.55
BM4339 99.25 - 97.69 96.19 91.7 85.15 80.7 72.93 72.65 56.83
CCRI-16110 98.8 98.67 - 97.2 91.54 85.51 80.54 72.81 72.73 57.07
N97-330 97.56 97.48 98.03 - 90.61 85.59 80.98 72.81 72.73 57.07
A902 95.16 95.23 95.29 94.63 - 89.84 85.43 73.34 73.13 61.52
N03-0072 91.93 91.94 92.15 92.22 94.2 - 89.56 71.48 71.72 65.65
GV5 87.26 87.46 87.23 87.72 89.92 92.43 - 72.08 72.61 75.72
N15-508 66.34 66.47 66.3 66.22 66.4 65.58 64.66 - 85.72 47.93
N04-0414 65.83 65.89 65.88 65.81 65.72 65.38 64.79 91.55 - 48.54
10/96A 63.09 63.28 63.06 63.54 65.75 68.25 75.1 53.46 53.73 -
Amino acid identities (%)b
Nucleotide identities (%)c  
 
aThe genetic information for VanD-type vancomycin resistant enterococci was obtained from the genome database in NCBI  
(http://www.ncbi.nlm.nih.gov/).  BM4339 (accession no.;AF130997.1), CCRI-16110 (accession no.;EF508033.1), N97-330 (accession 
no.;AF175293.1),  A902 (accession no.;EU999036.1), N03-0072 (accession no.;AY489045.1),  GV5 (accession no.;AB242319.1),  
N15-508 (accession no.; KT825491.1), N04-0414 (accession no.; DQ172830.1), 10/96A (accession no.; AY082011.1). 
b,cIdentities were calculated by ClustalW.  
 
